Delivery Order SPE2DB22D2006-SPE2DB25FW3YK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,452.05 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on August 21, 2025, with completion targeted for September 12, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AVEED (testosterone undecanoate) is a long-acting testosterone replacement therapy indicated for treating hypogonadism in...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $23,123.28 on August 7, 2025, for the supply of AVEED 750 mg/3 mL vials. This firm fixed-price delivery order, which has an ultimate completion date of August 28, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $14,452.05 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of AVEED 750 mg/3 mL vials. The contract represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $44,319.62 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on August 7, 2025, with completion targeted for August 28, 2025. This firm fixed-price delivery order, which was not set aside for small business, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's distribution center in...
- The Defense Logistics Agency awarded a $34,684.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of AVEED 750 MG/3 ML vials. The contract is competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of September 5, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The U.S. Defense Logistics Agency (DLA) awarded a $27,954.72 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of 4,565,717,571 units of AVEED 750 MG/3 ML VIAL 3ML, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999 through December 2025 for a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The...
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of AVEED 750 mg/3 mL vials. The contract, which is non-set-aside and competitively awarded, carries a firm fixed price structure with an ultimate completion date of August 12, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- This is a firm-fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of AVEED 750 MG/3 ML VIAL 3ML. The contract has a ceiling value of $23,295.60 and a period of performance through August 8, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the agency to procure a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,926.94 firm fixed-price delivery order is for the medical product "AVEED 750 MG/3 ML VIAL 3ML" and has an ultimate completion date of March 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award, with a ceiling value of $48,173.50, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order, is for the supply of AVEED 750 MG/3 ML VIAL 3ML, a pharmaceutical product. The contract is not designated as a set-aside and has an ultimate completion date of February 26, 2025. Amerisourcebergen Drug Corp, the awardee,...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3YKDelivery Order
The Defense Logistics Agency awarded a $69,369.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on September 2, 2025, with an ultimate completion date of September 23, 2025. This is a non-set-aside competitive award issued to the prime contractor's corporate office in Conshohocken, Pennsylvania. AVEED (testosterone undecanoate) is a long-acting testosterone replacement therapy used to treat hypogonadism, reflecting the DLA's ongoing commitment to supplying specialized pharmaceutical products for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. Through this prime IDC, AmerisourceBergen supplies an extensive range of pharmaceutical products and medical commodities to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The company's federal contract portfolio demonstrates substantial capability in fulfilling diverse medical procurement requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $69.4k | 9/2/25 |